Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Trial · NCT04852679
Adverse events70
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 70
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 9 | 43 | 10 |
| other | Alanine aminotransferase increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | Bilirubin conjugated increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 8 | 43 | 8 |
| other | Bilirubin conjugated increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | Blood bilirubin increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 8 | 43 | 9 |
| other | Blood bilirubin increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | Weight decreased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 8 | 43 | 10 |
| other | Weight decreased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | Blood glucose increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 7 | 43 | 7 |
| other | Blood glucose increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | White blood cell count decreased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 6 | 43 | 8 |
| other | White blood cell count decreased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | Glycosylated haemoglobin increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 5 | 43 | 5 |
| other | Glycosylated haemoglobin increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 1 | 5 | 1 |
| other | Blood thyroid stimulating hormone increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 4 | 43 | 4 |
| other | Blood thyroid stimulating hormone increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | Weight increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 4 | 43 | 4 |
| other | Weight increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
| other | Aspartate aminotransferase increased | Investigations | Main Intervention Period: Lanreotide Autogel 120 mg | 3 | 43 | 5 |
| other | Aspartate aminotransferase increased | Investigations | Independent Injection Period: Lanreotide Autogel 120 mg | 0 | 5 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04852679/events